Date: 2017-01-19
Type of information: Nomination
Compound: chief medical officer
Company: Genenta Science (Italy)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On January 19, 2017, Genenta Science, a biotech company focused on hematopoietic stem cell gene therapy for tumor treatment, announced that Carlo Russo is joining the company as Chief Medical Officer. Dr. Russo comes to Genenta from Adverum Biotechnologies, where he served as Chief Medical Officer. Previously, Dr. Russo held Senior Vice President roles at GSK, including: Founder and Manager of the Alternative Development Program, Head of the Cardiovascular and Metabolic Development Center, Founder and Head of Development of the Biopharm Unit, and most recently the Head of R&D for the Rare Disease Unit.
- Prior joining GSK, Dr. Russo was the President & CEO of Vaxinnate, a vaccine biotech startup, and before that he held senior roles in the Regulatory Department of Merck Vaccine & Biologics. Dr. Russo earned his doctorate degree in Medicine and Board Certification in Hematology at the University of Genoa Medical School. Dr. Russo’s academic appointments include: A Postdoctoral fellowship at the Scripps Research Institute in La Jolla, California, assistant professorship at the Columbia University, College Physicians and Surgeons,and Associate Professorship at the Cornell University Medical and Graduate Schools.
Financial terms:
Latest news:
Is general: Yes
